As the news of GLP-1 (Glucagon-like peptide-1)-type diabetes treatments being used in clinical settings is reported one after another, concerns about this are growing. According to the medical community on the 4th, Novo Nordisk Pharmaceutical Korea is currently informing the clinical site of the out-of-stock news of Xultophy, a GLP-1 series diabetes treatment.

Xultophy is a drug that controls blood sugar in adult type 2 diabetic patients and is a fixed ratio combination (FRC) of our company's basal insulin degludec and the GLP-1 analog liraglutide. After approval by the Ministry of Food and Drug Safety in Korea in 2019, it was applied as a benefit in May 2021 and is being used in clinical settings.